NCT03744806View on ClinicalTrials.gov

Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD

CompletedOBSERVATIONAL
Enrollment

48

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

September 30, 2015

Study Completion Date

August 31, 2018

Conditions
Exudative Age-related Macular Degeneration
Interventions
DRUG

Bevacizumab Injection

All Listed Sponsors
lead

Medical University of Lublin

OTHER

NCT03744806 - Blood-aqueous Barrier Integrity in Eyes Undergoing Intravitreal Bevacizumab Therapy to Treat Neovascular AMD | Biotech Hunter | Biotech Hunter